Skip to main content
Top
Published in: Clinical and Experimental Nephrology 2/2014

01-04-2014 | Review Article

Lipoprotein metabolism and CKD: overview

Author: Philip Barter

Published in: Clinical and Experimental Nephrology | Issue 2/2014

Login to get access

Abstract

Patients with chronic kidney disease (CKD) frequently display abnormalities of plasma lipids and lipoproteins. These abnormalities include hypertriglyceridemia associated with elevated levels of very low-density lipoproteins (VLDLs) and chylomicrons. There is often also an increase in the concentration of the atherogenic, cholesterol-enriched remnants of VLDLs and chylomicrons. The concentration of low-density lipoprotein cholesterol is usually normal, but there is frequently a decrease in concentration of the cardio-protective high-density lipoproteins. There is also often an increase in the concentration of the atherogenic lipoprotein (a) particles. This article provides an overview of plasma lipoprotein transport and identifies mechanisms responsible for the abnormalities observed in patients with CKD.
Literature
1.
2.
go back to reference Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18:1246–61.PubMedCrossRef Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol. 2007;18:1246–61.PubMedCrossRef
3.
go back to reference Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transpl. 1998;13:2281–7.CrossRef Rajman I, Harper L, McPake D, Kendall MJ, Wheeler DC. Low-density lipoprotein subfraction profiles in chronic renal failure. Nephrol Dial Transpl. 1998;13:2281–7.CrossRef
4.
go back to reference Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35:852–62.PubMedCrossRef Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ. Atherogenic lipoprotein phenotype in end-stage renal failure: origin and extent of small dense low-density lipoprotein formation. Am J Kidney Dis. 2000;35:852–62.PubMedCrossRef
5.
6.
go back to reference Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993;21:573–92.PubMed Attman PO, Samuelsson O, Alaupovic P. Lipoprotein metabolism and renal failure. Am J Kidney Dis. 1993;21:573–92.PubMed
7.
go back to reference Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and apo A-I expression in chronic renal failure. Nephrol Dial Transpl. 1999;14:1462–6.CrossRef Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and apo A-I expression in chronic renal failure. Nephrol Dial Transpl. 1999;14:1462–6.CrossRef
8.
go back to reference Haffner SM, Gruber KK, Aldrete G Jr, Morales PA, Stern MP, Tuttle KR. Increased lipoprotein(a) concentrations in chronic renal failure. J Am Soc Nephrol. 1992;3:1156–62.PubMed Haffner SM, Gruber KK, Aldrete G Jr, Morales PA, Stern MP, Tuttle KR. Increased lipoprotein(a) concentrations in chronic renal failure. J Am Soc Nephrol. 1992;3:1156–62.PubMed
9.
go back to reference Bairaktari E, Elisaf M, Tsolas O, Siamopoulos KC. Serum Lp(a) levels in patients with moderate renal failure. Nephron. 1998;79:367–8.PubMedCrossRef Bairaktari E, Elisaf M, Tsolas O, Siamopoulos KC. Serum Lp(a) levels in patients with moderate renal failure. Nephron. 1998;79:367–8.PubMedCrossRef
10.
go back to reference Barter PJ, Nicholls SJ, Rye K-A, Anantharamaiah GM, Navab M, Fogelman AM. Anti-inflammatory properties of HDL. Circ Res. 2004;95:764–72.PubMedCrossRef Barter PJ, Nicholls SJ, Rye K-A, Anantharamaiah GM, Navab M, Fogelman AM. Anti-inflammatory properties of HDL. Circ Res. 2004;95:764–72.PubMedCrossRef
11.
go back to reference Fryirs MA, Barter PJ, Appavaroo M, Tuch BE, Tabet F, Heather AK, Rye KA. Effects of high-density lipoproteins on pancreatic {beta}-cell insulin secretion. Arterioscler Thromb Vasc Biol. 2010;30:1642–8.PubMedCrossRef Fryirs MA, Barter PJ, Appavaroo M, Tuch BE, Tabet F, Heather AK, Rye KA. Effects of high-density lipoproteins on pancreatic {beta}-cell insulin secretion. Arterioscler Thromb Vasc Biol. 2010;30:1642–8.PubMedCrossRef
12.
go back to reference Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 1996;50:1928–35.PubMedCrossRef Vaziri ND, Liang K. Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int. 1996;50:1928–35.PubMedCrossRef
13.
go back to reference Vaziri ND, Yuan J, Ni Z, Nicholas SB, Drew CR, Norris KC. Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Clin Exp Nephrol. 2012;16:238–43.PubMedCentralPubMedCrossRef Vaziri ND, Yuan J, Ni Z, Nicholas SB, Drew CR, Norris KC. Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression. Clin Exp Nephrol. 2012;16:238–43.PubMedCentralPubMedCrossRef
14.
go back to reference Mordasini R, Frey F, Flury W, Klose G, Greten H. Selective deficiency of hepatic triglyceride lipase in uremic patients. N Engl J Med. 1977;297:1362–6.PubMedCrossRef Mordasini R, Frey F, Flury W, Klose G, Greten H. Selective deficiency of hepatic triglyceride lipase in uremic patients. N Engl J Med. 1977;297:1362–6.PubMedCrossRef
15.
go back to reference Vaziri ND, Liang K, Parks JS. Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001;59:2192–6.PubMedCrossRef Vaziri ND, Liang K, Parks JS. Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001;59:2192–6.PubMedCrossRef
16.
go back to reference Guarnieri GF, Moracchiello M, Campanacci L, et al. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl. 1978;(8):S26–30. Guarnieri GF, Moracchiello M, Campanacci L, et al. Lecithin-cholesterol acyltransferase (LCAT) activity in chronic uremia. Kidney Int Suppl. 1978;(8):S26–30.
17.
go back to reference Kimura H, Miyazaki R, Imura T, et al. Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney Int. 2003;64:1829–37.PubMedCrossRef Kimura H, Miyazaki R, Imura T, et al. Hepatic lipase mutation may reduce vascular disease prevalence in hemodialysis patients with high CETP levels. Kidney Int. 2003;64:1829–37.PubMedCrossRef
18.
go back to reference Dirican M, Akca R, Sarandol E, Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol. 2004;17:813–8.PubMed Dirican M, Akca R, Sarandol E, Dilek K. Serum paraoxonase activity in uremic predialysis and hemodialysis patients. J Nephrol. 2004;17:813–8.PubMed
19.
go back to reference Liberopoulos EN, Papavasiliou E, Miltiadous GA, et al. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int. 2004;24:580–9.PubMed Liberopoulos EN, Papavasiliou E, Miltiadous GA, et al. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int. 2004;24:580–9.PubMed
20.
go back to reference Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, Rye KA. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia. 2007;50:643–53.PubMedCrossRef Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, Rye KA. The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia. 2007;50:643–53.PubMedCrossRef
Metadata
Title
Lipoprotein metabolism and CKD: overview
Author
Philip Barter
Publication date
01-04-2014
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 2/2014
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-013-0866-9

Other articles of this Issue 2/2014

Clinical and Experimental Nephrology 2/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.